Loading...
Progression of Untreated Minimally Active Chronic HBV Infection Compared to Inactive Infection
Зохиогч
Lee, Hye Won
Kim, Seung Up
Park, Jun Yong
Ahn, Sang Hoon
Han, Kwang-Hyub
Kim, Beom Kyung
Он
2019 оны арван хоёрдугаар сар
Төрөл
journal article
Хэвлэгч
Elsevier BV
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Volume
17
Issue
13
Start Page
2808
End Page
2810.e2
ISSN
1542-7714
Хураангуй
Nucleos(t)ide analogs (NUCs) are recommended when both are fulfilled in the absence of hepatocellular carcinoma (HCC) or cirrhosis; (1) elevated serum hepatitis B virus (HBV)-DNA (≥20,000 IU/mL for hepatitis B e antigen-positive chronic hepatitis B [CHB] or ≥2000 IU/mL for hepatitis B e antigen-negative CHB) and (2) serum alanine aminotransferase ≥2× upper limit of normal.1 Therefore, many patients still remain untreated. Such untreated patients have so called "minimally active CHB," where serum HBV-DNA is persistently >2000 IU/mL and other parameters for NUCs are below the criteria.2 There have been little data concerning their prognosis.
